Drugs / PELITREXOL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00017524 | Mar 2001 → Nov 2004 | cancer of unknown primary site | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00090701 | Sep 2004 → ? | lung neoplasm | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00078468 | Dec 2003 → Sep 2004 | colorectal cancer | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PELITREXOL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00078468 ↗ |
| Known as | AG-2037 | “PELITREXOL/AG-2037” NCT00078468 ↗ |
| Action | Inhibit | “GAR transformylase inhibitor” CHEMBL2107361 ↗1“GARFT Inhibitor AG2037” NCT00078468 ↗ |
| Modality | Small molecule | — CHEMBL2107361 ↗ |
| Target | GART | “GAR transformylase inhibitor” CHEMBL2107361 ↗ |